Anika Therapeutics | ANIK - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Abbott USD 1.74B 23.39B 2025-09
Agenus USD 35.32M 2.51M 2025-12
Agios Pharmaceuticals USD 58.45M 169K 2025-12
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 135.7M 2.44M 2025-09
Enanta Pharmaceuticals USD 212K 1000 2023-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Integra LifeSciences USD 77.89M 34K 2025-12
Intrexon USD 0 0 2024-06
J&J USD 2.41B 584K 2025-09
Karyopharm Therapeutics USD 13K 0 2024-09
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.32M 60K 2025-12
Merit Medical Systems USD 59.29M 72K 2025-09
Rigel Pharmaceuticals USD 17K 158K 2024-06
Smith & Nephew USD 875.96M 1.61M 2025-12
Stryker USD 382.4M 93K 2025-12
Surmodics USD 716K 4K 2024-09
Veracyte USD 79.05M 377K 2025-12
Xencor USD 71.87M 529K 2025-12
Zimmer Biomet Holdings USD 198.18M 18.44K 2025-12